Clinical trial simulation of antiviral drugs
Journal of Virology · 2026
DOI: 10.1128/jvi.01814-24 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Virology, 2026. Verfasst von Joshua T Schiffer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Fred Hutchinson Cancer Center, Vaccine and Infectious Diseases Division, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Clinical Trials as Topic, Virus Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 296 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Antiviral clinical trial simulation (CTS) is a type of mathematical modeling that couples viral- immune dynamics (VID) unique to each human viral pathogen, with mechanistic, pharmacokinetic (PK), and pharmacodynamic (PD) drug characteristics. Validation is achieved by matching model output to detailed viral load trajectories from trials. Antiviral CTS can be applied at all stages of drug development to viruses with distinct shedding patterns. Models can capture the activity of small molecules, neutralizing antibodies, and cellular therapies, as well as combination strategies to enhance potency and avoid drug resistance. Several principles are observed across antiviral CTS models. First, PK and PD models that recapitulate drug levels and concentration-dependent antiviral activity are often necessary, but never sufficient to predict trial results. VID equations are also required to guide optimal treatment timing because expanding immune responses synergistically eliminate infection but are deleterious if too sustained or intense. Therefore, equivalent antiviral doses may have different efficacy if given during different infection stages. Second, antiviral CTS models identify effective plasma drug concentrations in humans, which are often poorly predicted by in vitro assays. Finally, models that do not consider drug mechanisms lead to incorrect efficacy estimates. Data-validated CTS is increasingly used to inform drug dose and dosing interval, treatment timing and duration, virologic endpoint selection, and sample size, particularly when applied to detailed phase 1 and 2 trial data. Given the high expense of antiviral licensure trials, CTS models are vital to optimize trial efficacy and de-risk the drug development process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fred Hutchinson Cancer Center, Vaccine and Infectious Diseases Division, Seattle, Washington, USA.
- Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
- Department of Global Health, University of Washington, Seattle, Washington, USA.
- Palo Alto VA, Palto Alto, California, USA.
- University of California, San Francisco, San Francisco, California, USA.
- Interdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan.
ORCID-Profile: Joshua T Schiffer, Daniel B Reeves, Ugo Avila-Ponce de Leon
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Schiffer, J. T., Reeves, D. B., Mayer, B., Rodriguez, L. R., Duke, E. R., Haddock, B., Avila-Ponce de Leon, U., Iwami, S., Owens, K., & Esmaeili-Wellman, S. (2026). Clinical trial simulation of antiviral drugs. Journal of Virology. https://doi.org/10.1128/jvi.01814-24
Vancouver
Schiffer JT, Reeves DB, Mayer B, Rodriguez LR, Duke ER, Haddock B, et al. Clinical trial simulation of antiviral drugs. Journal of Virology. 2026. doi:10.1128/jvi.01814-24
BibTeX
@article{Schiffer2026,
author = {Schiffer, Joshua T and Reeves, Daniel B and Mayer, Bryan and Rodriguez, Lucero Rodriguez and Duke, Elizabeth R and Haddock, Beatrix and Avila-Ponce de Leon, Ugo and Iwami, Shingo and Owens, Katherine and Esmaeili-Wellman, Shadi},
title = {Clinical trial simulation of antiviral drugs},
journal = {Journal of Virology},
year = {2026},
doi = {10.1128/jvi.01814-24}
}
EUVIMED